Form 8-K - Current report:
SEC Accession No. 0001213900-25-035668
Filing Date
2025-04-25
Accepted
2025-04-25 17:18:52
Documents
15
Period of Report
2025-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239604-8k_pluri.htm   iXBRL 8-K 30636
2 FORM OF PRE-FUNDED WARRANT ea023960401ex4-1_pluri.htm EX-4.1 78460
3 AMENDMENT TO SECURITIES PURCHASE AGREEMENT ea023960401ex10-1_pluri.htm EX-10.1 17789
  Complete submission text file 0001213900-25-035668.txt   327420

Data Files

Seq Description Document Type Size
4 EX-101.SCH plur-20250425.xsd EX-101.SCH 3029
5 EX-101.SCH plur-20250425_lab.xml EX-101.LAB 34239
6 EX-101.SCH plur-20250425_pre.xml EX-101.PRE 22368
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239604-8k_pluri_htm.xml XML 3680
Mailing Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409
Business Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 972-74-710-7171
Pluri Inc. (Filer) CIK: 0001158780 (see all company filings)

EIN.: 980351734 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31392 | Film No.: 25875249
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)